A Population Pharmacokinetic Modeling Approach to Determine the Efficacy of Intravenous Amikacin in Children with Cystic Fibrosis

Conclusions: For intermediate pathogens, a dose of at least 40 mg/kg/d can improve efficacy, with an acceptable calculated residual trough level in cases of normal or hyperfiltration. Because amikacin undergoes renal clearance, which is immature until 1 year of age, dosing recommendations for this age group may be markedly high, warranting cautious interpretation.
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Dr. Roger Jelliffe Memorial Issue: Focus on Personalized Dosing Strategies Source Type: research